Primary links
Curiel Lab
The Curiel lab is a cancer research laboratory run by principal primary investigator Tyler Curiel, MD, MPH. The lab is associated with the Cancer Therapy and Research Center (CTRC) at University of Texas Health Science Center San Antonio (UTHSCSA). Primary research centers around tumor immunology and infectious diseases (Michael Brumlik, PHD is the primary principal investigator for the infectious diseases track).
General facts:
- Approximately 12,000 square feet of space, with 6,000 feet dedicated lab space.
- State-of-the art equipment.
Tyler Curiel, MD, MPH
Tyler Curiel, MD, MPH is the primary principal investigator for immunology and infectious diseases at the Curiel/Brumlik lab.
Dr. Curiel has a particular interest in developing immune therapies for cancers and infectious diseases by boosting the body's immune system. He holds patents and patents-pending for novel therapies for infectious diseases and cancers. He received the 2002 Johnson&Johnson Focused Giving Award for novel drug development. Findings from his ovarian cancer research were published this past year in two issues of the prestigious journal Nature Medicine.
Faculty Profile:
Recent Publications:
email:
Phone number:
210-450-1407
Tahiro Shin, MD, PHD
Tahiro Shin is an independent PI working in the Curiel lab. The major goal of his research is to discover immediate translational potential for new cancer immunotherapies.
Recent Publications:
email:
Phone number:
210-562-5295
Bin Zhang, MD, PHD
Bin Zhang is an independent PI working in the Curiel lab.
Dr. Zhang's work functions as an integrated translational research program
with the goal of designing and developing new immunotherapies and
immunologic strategies for cancer treatment and prevention. The project is
focused on effector and regulatory molecules controlling cancer specific
lymphocytes before and during immunotherapy, especially studying a negative
immunoregulatory mechanism used for immune evasion in tumor
microenvironment.
Ongoing studies involve:
- analysis and utilization of newly found costimulatory molecules from the perspective of cancer immunology;
- To develop a novel DC immunization strategy to overcome tumor-mediated
- immunosuppression;
- To study the age-related immune defect (Immunosenescence)
Faculty Profile:
Recent Publications:
email:
Phone number:
210-562-5243
Michael Brumlik, PHD
Michael Brumlik, PHD, is the primary principal investigator for infectious diseases at the Curiel/Brumlik lab.
His research focuses on the immunological consequences of cancer and infection. He currently uses Toxoplasma gondii as the basis for his infection model, although other protozoan parasites are also of interest. In terms of cancer, [the laboratory has] currently developed an ovarian cancer mouse model but also have some expertise using melanoma (B16) and breast cancer (ANV) mouse models as well. Regulatory T cells (Tregs) play a significant role in immune dysfunction within the tumor microenvironment and defeat immune surveillance in cancer patients. Since no unique biomarker has yet been identified on Tregs, the lab is interested in developing novel means of detecting and depleting Tregs.
Faculty Profile:
Recent Publications:
email:
Phone number:
210-562-5276